Slagter, A.E.; Caspers, I.A.; van Grieken, N.C.T.; Walraven, I.; Lind, P.; Meershoek-Klein Kranenbarg, E.; Grootscholten, C.; Nordsmark, M.; van Sandick, J.W.; Sikorska, K.;
et al. Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer. Cancers 2022, 14, 2963.
https://doi.org/10.3390/cancers14122963
AMA Style
Slagter AE, Caspers IA, van Grieken NCT, Walraven I, Lind P, Meershoek-Klein Kranenbarg E, Grootscholten C, Nordsmark M, van Sandick JW, Sikorska K,
et al. Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer. Cancers. 2022; 14(12):2963.
https://doi.org/10.3390/cancers14122963
Chicago/Turabian Style
Slagter, Astrid E., Irene A. Caspers, Nicole C. T. van Grieken, Iris Walraven, Pehr Lind, Elma Meershoek-Klein Kranenbarg, Cecile Grootscholten, Marianne Nordsmark, Johanna W. van Sandick, Karolina Sikorska,
and et al. 2022. "Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer" Cancers 14, no. 12: 2963.
https://doi.org/10.3390/cancers14122963
APA Style
Slagter, A. E., Caspers, I. A., van Grieken, N. C. T., Walraven, I., Lind, P., Meershoek-Klein Kranenbarg, E., Grootscholten, C., Nordsmark, M., van Sandick, J. W., Sikorska, K., van de Velde, C. J. H., Jansen, E. P. M., Verheij, M., van Laarhoven, H. W. M., & Cats, A.
(2022). Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer. Cancers, 14(12), 2963.
https://doi.org/10.3390/cancers14122963
